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 Neural progenitor cells derived from induced pluripotent stem cells have been 
considered as a potential source for cell-transplantation therapy of central nervous 
disorders. However, efficient methods to expand neural progenitor cells are further required 
for their clinical applications. In this study, a protein array was fabricated with nine 
extracellular matrices and used to screen substrates suitable for the expansion of neural 
progenitor cells derived from mouse induced pluripotent stem cells. The results showed that 
neural progenitor cells efficiently proliferated on substrates with immobilized laminin-1, 
laminin-5, or Matrigel. Based on this result, further attempts were made to develop 
clinically compliant substrates with immobilized polypeptides that mimic laminin-1, one of 
the most effective extracellular matrices as identified in the array-based screening. We used 
here recombinant DNA technology to prepare polypeptide containing the globular domain 
3 of laminin-1 and immobilized it onto glass-based substrates. Our results showed that 
neural progenitor cells selectively proliferated on substrate with the immobilized 
polypeptide while maintaining their differentiated state. 
 








 Neural progenitor cells (NPCs) undergo self-renewal and differentiation into 
neuronal and glial lineages and considered as a promising cell source for the treatment of 
central nervous system disorders such as Parkinson’s disease (Dyson et al.,  2011), spinal 
cord injury (Tetzlaff et al.,  2011), and traumatic brain injury (Gögel et al.,  2011). NPCs 
isolated from fetal human brain tissues have been transplanted for the treatment of a patient 
with Parkinson’s disease (Freed et al., 2001). However, the limitation of donor cells and 
ethical concerns make this therapy difficult to clinically apply. Embryonic stem (ES) cells 
and induced pluripotent stem (iPS) cells are other candidate cell sources for stem cell-based 
transplantation therapies (Robinton et al., 2012). These cells can unlimitedly proliferate in 
vitro and differentiate into multiple types of functional cells. Recently, two clinical trials 
using human ES-derived cells were started (Solbakk et al., 2011; Schwartz et al., 2012). In 
addition, iPS-derived cells may be useful for studying the mechanisms underlying the 
progression of central nervous system disorders and for developing effective treatments for 
associated diseases (Bellin et al., 2012).  
 Various protocols have been reported for the differentiation of iPS cells into a 
neural lineage (Czepiel et al., 2011; Cai, et al., 2010; Selvaraj et al., 2012). It was also 
reported that neural cells derived from iPS cells had been successfully integrated into the 
animal brain and spinal cord (Nori et al., 2011; Rhee et al., 2011). iPS cell-derived neural 
cells improved the motor function of the animals to a certain degree. Although neural cells 
derived from pluripotent stem cells are considered to have utility in cell replacement 
therapy, various difficulties still remain to be overcome. First, graft rejection by the host 
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immune system is unavoidable in transplantation therapy and should be carefully 
controlled. When cells derived from ES cells are used, the graft is expected to be 
recognized as allogeneic tissue and thus will be rejected by the host immune system 
(Bradley et al., 2002; Drukker et al., 2004; Taylor et al., 2011). Even when iPS cells are 
derived from a patient, however, the reprogramming protocols may affect the 
immunogenicity of the grafts (Taylor et al., 2011). Second, tumor formation must be 
carefully considered in cell transplantation therapy using iPS-derived cells (Hentze et al., 
2010; Fong et al., 2010). Undifferentiated pluripotent stem cells and progenitor cells 
contained in transplants may proliferate and overgrow in the host brain (Li et al., 2008).   
Most of the applications mentioned above require an in vitro culture that allows the 
proliferation of NPCs without altering their properties. Extracellular matrices (ECMs) play 
pivotal roles in the maintenance of various stem and progenitor cells in native tissues (Kim 
et al., 2011) and in the behaviors of neural cells (Wojcik-Stanaszek et al., 2011). In the 
present study, protein arrays (Soen et al., 2006; Nakajima et al., 2007) were fabricated with 
various ECMs and used to screen for the proliferation of NPCs derived from mouse iPS 
(miPS) cells. Array-based assays enable high-throughput screening of substrates with 
immobilized proteins and synthetic polymers (Little et al., 2011; Derda et al., 2007; Derda 
et al., 2010).  Based on the results of the ECM screening, globular domain 3 (LG3), a part 
of the laminin 1 chain, was synthesized as a fusion with a hexahistidine sequence (His-
tag).  LG3 is relatively small domain (16.5 kDa) and known to efficiently bind with 61 
integrin (Ido et al., 2004). The engineered protein was anchored through the coordination of 
 6
the His-tag with Ni2+ ions bound on a glass plate, and feasibility of the substrate with 
surface-immobilized LG3 was examined for the proliferation of NPCs. 
 
   
Materials and Methods  
 
Maintenance of miPS cells and their differentiation into NPCs 
 
 miPS cells (20D17) (Okita et al., 2007) were obtained from the Riken cell bank 
(Ibaraki, Japan). The cells had been transformed to express GFP driven by the promoter of 
Nanog. miPS cells maintained on a feeder layer of mouse embryonic fibroblasts in DMEM 
(Invitrogen Corp., Carlsbad, CA, USA) containing 15% fetal bovine serum, 0.1 mM MEM 
non-essential amino acids, 0.1 mM 2-mercaptoethanol, 1000 U/mL leukemia inhibitory 
factor (Millipore, Billerica, MA, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin. 
For differentiation, miPS cells were collected as single cells by treatment with 0.05% 
trypsin solution containing 0.53 mM ethylenediamine- N,N,N’,N’-tetraacetic acid (EDTA). 
The cells were seeded to a gelatin-coated dish and incubated for 40 min to allow for 
depleting feeder cells possibly present in a population, and then unattached miPS cells were 
recovered for the later experiments.  
 The neurosphere method was used to induce neural cells from miPS cells (Okada et 
al., 2008). miPS cells were suspended in DMEM/F12 (1:1) containing 2% (v/v) B27 
supplement (Invitrogen), 5 μg/mL heparin, 100 U/mL penicillin, and 100 μg/mL 
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streptomycin (hereafter referred to as base medium) supplemented with 20 ng/mL 
epidermal growth factor (EGF, Wako Pure Chemical Industries, Osaka, Japan), 20 ng/mL 
basic fibroblast growth factor (bFGF, Wako), and 10 nM retinoic acid (Sigma, St. Louis, 
MO, USA), and then plated at a density of 8.5×103 cells/cm2 onto a tissue culture dish 
previously coated with Pluronic F127 (Sigma). Every 5-7 days, floating cell aggregates 
were collected and dissociated into single cells by treatment with AccuMax (Innovative 
Cell Technologies, Inc., San Diego, CA, USA) containing 0.05% trypsin, and subcultured 
to form secondary aggregates. Dissociation and aggregation were repeated to obtain fourth-
generation aggregates. 
 
Preparation of ECM arrays 
 
  ECMs were covalently immobilized onto the glass surface. First, amine groups were 
introduced on the surface of glass plates (22 mm × 26 mm × 0.5 mm) by treating with 
aminopropyltriethoxysilane (APTES; Shin-Etsu Chemical Co., Ltd., Tokyo, Japan) 
(Konagaya et al., 2011). These plates were immersed in 10% (v/v) aqueous glutaraldehyde 
solution for 1 h at room temperature to introduce aldehyde groups. After washing the plates 
with water, a silicone frame with multiple circular windows (2 mm in diameter, 5 × 4 
windows) was mounted on top of each glass plate to make a microwell array. ECM 
solutions in phosphate-buffered saline (PBS) containing  50 μg/mL collagen I (Cellmatrix 
type I, porcine tendon, Nitta Gelatin, Inc., Osaka, Japan), 50 μg/mL collagen IV 
(Cellmatrix type IV, bovine crystalline lens, Nitta Gelatin, Inc.), 50 μg/mL gelatin (porcine 
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skin, Sigma), 50 μg/mL laminin-1 (mouse Engelbreth-Holm-Swarm sarcoma, Invitrogen), 
50 μg/mL Matrigel (mouse Engelbreth-Holm-Swarm sarcoma, BD Biosciences, San Jose, 
CA, USA), 50 μg/mL fibronectin (human serum, BD Biosciences), 50 μg/mL vitronecitn 
(Sigma), 50 μg/mL ProNectin F (synthetic ECM, Sanyo Chemical Industries Ltd., Kyoto, 
Japan), or 2 μg/mL laminin-5 (human recombinant, Oriental Yeast Co., Ltd., Tokyo, Japan) 
were separately pipetted into different wells on a single array (15 μL for each well). Among 
the ECMs used, ProNectin F is a commercially available synthetic ECM consisting of cell-
adhesive arginine-glycine-aspartic acid (RGD) residues connected with β-sheet-forming 
hydrophobic segments. All ECMs were immobilized on the glass surface through Schiff 
base formation between aldehydes and amines contained in proteins. After 1 h, the ECM 
array was washed with PBS to remove unbound proteins. As a control surface, PBS 
containing 1 M ethanolamine was used instead of protein solutions. Ethanolamine was used 
to block unreacted aldehyde groups of the glass surface. Summary of the preparation of 
ECM array was shown in supporting figure 1.  
 
Amounts of immobilized ECM proteins 
 
 ECMs were separately immobilized onto the surfaces of glass plates (22 mm × 26 
mm × 0.5 mm) through the method similar to that described above. The amounts of 
immobilized ECM proteins were determined using the Micro BCA Protein Assay Kit 
(Thermo, Waltham, MA, USA). A silicone frame with a square window (inner area: 4 cm2) 
was placed on the ECM-immobilized surface. The Micro BCA reaction mixture (150 L) 
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was pipetted into the window, and the temperature was maintained at 37 C for 2 h to allow 
for the color reaction. The absorbance of the resulting solution was measured at 562 nm 
using a spectrophotometer (SpectraMaxTM 2Me, Molecular Devices, LLC, Sunnyvale, CA, 





 NPC-containing cell aggregates of 4th generation were dissociated into single cells by 
treatment with AccuMax containing 0.05% trypsin. The cells were suspended in base 
medium supplemented with 20 ng/mL EGF and 20 ng/mL bFGF (Okada et al., 2008). The 
cells were applied to each spot of an ECM array at a density of 2.0  104 cells/cm2 and 
incubated for 3 d at 37 C under 5% CO2 atmosphere. The expression of various marker 




 Cells were fixed with PBS containing 4% paraformaldehyde and then permeabilized 
by treatment with 0.2% Triton X-100 solution for 15 min at room temperature. The cells 
were then treated with Blocking One reagent (Nacalai Tesque, Kyoto, Japan) for 90 min to 
inhibit nonspecific adsorption of antibodies, followed by binding of primary antibodies 
against octamer-binding transcription factor 3/4 (Oct-3/4; 1:50, mouse monoclonal, Santa 
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Cruz Biotechnology, Inc., Santa Cruz, CA, USA), green fluorescent protein (GFP; 1:1000, 
chicken polyclonal, Millipore), nestin (1:200, mouse monoclonal, BD Biosciences), or -
tubulin III (1:500, rabbit monoclonal, Covance, Princeton, NJ, USA) for 1 h at room 
temperature. After washing with PBS containing 0.05% Tween 20, cells were treated with a 
solution of Alexa Fluor 594 anti-mouse IgG, Alexa Fluor 488 anti-rabbit IgG, or Alexa 
Fluor 488 anti-chicken IgG (Invitrogen) at a dilution of 1:500 for 1 h at room temperature 
and washed with PBS containing 0.05% Tween 20. Then, cell nuclei were counterstained 
with 1 μg/mL Hoechst 33258 (Dojindo Laboratories, Kumamoto, Japan). The localization 
of secondary antibodies was analyzed with a fluorescence microscopy (BX51 TRF, 
Olympus Optical Co., Ltd., Tokyo, Japan). Cells reactive for antibodies to nestin were 
counted on the merged images with nuclei staining. The original images were recorded at a 
magnification of 200, and individual cells were carefully identified on merged images.  
 
Preparation of His-tagged human LG3  
 
 The preparation of human LG3 (MW = 16.5 kDa) carrying hexahistidine residues at 
the terminus (LG3-His) was previously reported (Nakaji et al., 2012). Briefly, 
complementary DNA (cDNA) for human LG3 was obtained by polymerase chain reaction 
using human brain cDNA libraries (Takara Bio Inc., Shiga, Japan) as templates and specific 
primers. The resulting DNA fragments were extended with an N-terminal linker and a His-
tag sequence, and then inserted into the multiple cloning site of the pET22 vector 
(Millipore). The protein was expressed in Escherichia coli (BL21 codonplus strain). LG3-
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His, obtained as inclusion bodies, was extracted under denaturing conditions with 8 M urea, 
purified using a Ni2+-chelated affinity column (His Trap HP; GE Healthcare Bio-Science 
Corp., Piscataway, NJ, USA), and refolded by dialyzing against solutions in the presence of 
reduced and oxidized glutathione. The purity of LG3-His was checked by sodium 
dodecylsulfate-polyacrylamide gel electrophoresis. The concentration of LG3-His was 
determined using the Micro BCA Protein Assay Kit (Thermo). The solution of purified 
LG3-His was stored at –80 C until use. 
 
Immobilization of LG3-His on glass surfaces 
 
 LG3-His was immobilized on glass surfaces via chelation of Ni2+ with the His-tag, as 
previously described (Konagaya et al., 2011). Briefly, cleaned glass plates (22 mm × 26 
mm × 0.5 mm; Matsunami Glass Ind. Ltd., Osaka, Japan) were immersed in 5% (v/v) 
APTES in toluene for 1 h at room temperature, then washed with ethanol and water. The 
plates were placed in a vacuum oven and heated to 80 C for 3 h to obtain glass plates 
surface-modified with APTES, which carries an amino group at its terminus. The APTES-
modified glass plates were immersed in 10% (v/v) aqueous glutaraldehyde (Nacalai 
Tesque) for 30 min at room temperature to introduce aldehyde groups. The plates were then 
washed with water to remove unreacted glutaraldehyde. Then, a 10 mM aqueous solution 
of N-(5-amino-1-carboxypentyl) iminodiacetic acid (Dojindo Laboratories) was applied 
onto the activated surface, the plates were kept at room temperature for 2 h, and then 
washed with water to remove unreacted N-(5-amino-1-carboxypentyl) iminodiacetic acid. 
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The glass plates were immersed in 40 mM NiSO4 for 30 min at room temperature to form 
Ni2+ chelates, and then washed with water. The solution of LG3-His in PBS (3 μM) was 
plated onto the Ni2+-chelated surface and kept for 1 h at room temperature to allow for the 
immobilization of LG-His. The amount of immobilized LG3-His was determined using the 
Micro BCA Protein Assay Kit (Thermo). As a control, substrates with immobilized 
laminin-1 or ethanolamine were prepared. 
 
NPC culture on the LG3-immobilized substrate 
 
 NPC-containing cell aggregates of 4th generation were dissociated into single cells by 
treatment with AccuMax containing 0.05% trypsin. The cells were suspended in base 
medium supplemented with 20 ng/mL EGF and 20 ng/mL bFGF. The cells were seeded 
onto the LG3- or laminin-1-immobilized substrate at a density of 2.0  104 cells/cm2 and 
incubated for 3 d at 37 C under 5% CO2 atmosphere. 
 
miPS cell culture on LG3-immobilized substrate 
 
 Undifferentiated miPS cells were collected as single cells by treatment with 0.05% 
trypsin solution containing 0.53 mM EDTA. The cells were suspended in DMEM/F12 
containing 15% fetal bovine serum, 0.1 mM MEM non-essential amino acids, 0.1 mM 2-
mercaptoethanol, 1000 U/mL leukemia inhibitory factor, 100 U/mL penicillin, and 100 
μg/mL streptomycin. The cells were seeded onto the LG3- or laminin-1-immobilized 
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substrate at a density of 2.0  104 cells/cm2 and cultured for 3 d at 37 C under 5% CO2 
atmosphere. After 24 h and 72 h, phase-contrast images were recorded at a magnification of 
200, and the number of cells that adhered to the substrate was counted on the images by 




 The data were compared by means of one-way analysis of variance (ANOVA), 
followed by Tukey's honestly significance difference (HSD) test. All statistical analyses 





Induction of miPS cells into a neural linage 
 
 miPS cells used in this study had been transformed to express GFP driven by the 
promoter of Nanog, known as a key transcription factor to maintain cells in the 
undifferentiated state.  miPS cells were detached from a feeder cell layer and cultured as 
neurosphere-like aggregates in the presence of a low concentration (10 nM) of retinoic acid 
to differentiate miPS cells into a neural lineage. The time schedule for differentiation is 
shown in Fig. 1a. Although the GFP expression level of the aggregated cells gradually 
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decreased during the first 5 d of culture, most cells still expressed GFP and an 
undifferentiated marker Oct-3/4 in primary aggregates (Fig. 1 b and c). To induce 
differentiation into NPCs, aggregates were dissociated into single cells and further cultured 
in suspension in the presence of retinoic acid. In contrast to the primary aggregates, the 
majority of cells in the 4th-generation aggregates expressed neither GFP nor Oct-3/4, but 
expressed nestin and -tubulin III, markers of NPCs and of neurons, respectively. During 
repeated subcultures, the NPC population was enriched, and nestin-positive cells reached 
more than 70% of the total cells at the end of the 4th aggregate culture (Fig. 1d). Cells 
obtained from the 4th-generation aggregates were used for the following array-based 
assays. 
 
Immobilization of ECM proteins 
 
 Nine ECMs (collagen I, collagen IV, gelatin, laminin-1, laminin-5, Matrigel, 
fibronectin, vitronectin, and ProNectin F) were separately immobilized on glass surfaces. 
As shown in Fig. 2, the amounts of immobilized ECMs after extensive washing with PBS 
were determined to be 0.05‒0.5 μg/cm2. The observed low density of laminin-5 was 
probably caused by the low concentration (2 μg/mL) of the laminin-5 solution used, 
compare to the other proteins (50 μg/mL). This was simply because laminin-5 of higher 
concentration was not commercially available.  
 
Array-based screening of ECMs for NPC proliferation  
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 Fourth-generation aggregates were dissociated into single cells and seeded to the 
ECM array to examine the effect of ECMs on NPC proliferation. As a negative control, 
ethanolamine was used instead of ECMs.  Figure 3 shows the number of cells adhering to 
various substrates with immobilized ECMs 24 h after cell seeding. As is seen, laminin-1, 
laminin-5, Matrigel, and fibronectin were effective for cell adhesion, but vitronectin, 
collagen I, collagen IV, gelatin, and ProNectin F were relatively ineffective. Fluorescence 
micrographs of cells cultured on ECM arrays and then immunologically stained for nestin 
and β-tubulin III are shown in Fig. 4a. The majority of cells were positive only for nestin, 
but small numbers of β-tubulin III-positive cells were found on all ECM-immobilized 
substrates. After 3 d of culture, cell numbers increased approximately 10-fold on the most 
substrates. Among the substrates with various ECMs, nestin-positive cells most efficiently 
proliferated on the substrate with laminin-1, laminin-5, and Matrigel (Fig. 4b), yielding 
populations rich in nestin-positive cells (more than 95% of cells). Although the amount of 
immobilized laminin-5 was at least 3-fold or so lower than the levels of the other ECMs 
(Fig. 2), the laminin-5-immobilized surface effectively mediated adhesion and facilitated 
expansion of NPCs derived from miPS cells (Figs. 3 and 4). 
 
Expansion of NPCs on LG3-immobilized substrate 
 
 The surface with immobilized LG3 domain of a laminin 1 chain (an  chain 
contained in laminin-1) was examined as a culture substrate for the proliferation of NPCs 
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because a chemically defined and xeno-free cell culture substrate will be required for future 
clinical applications. LG3 was fused with a His-tag through recombinant DNA technology 
and immobilized onto the Ni2+-bound glass surface through coordination as previously 
reported (Konagaya et al., 2011). The amounts of immobilized LG3-His was determined to 
be 0.50 ± 0.11 μg/cm2. Figure 5a shows a phase-contrast micrograph of 4th generation 
aggregate cells that were seeded to and cultured on the LG3-immobilized substrate for 3 d. 
NPCs adhered and proliferated on the LG3-immobilized substrate as well as on the 
laminin-1-immobilized substrate. On the LG3-immobilized substrate, most of cells 
expressed nestin after 3 d of culture, while a few cells expressed -tubulin III (Fig. 5b). 
Overall, 98.3 ± 1.6% and 98.0 ± 0.1% of cells expressed nestin when cultured on the LG3- 
and laminin-1-immobilized substrates, respectively. Cell numbers increased 6-fold and 10-
fold on LG3- and laminin-1-immobilized surfaces, respectively (Fig. 5c). These increases 
were significantly higher than those determined for the control surface reacted with 
ethanolamine (no protein on the surface).   
 It was striking to observe that highly proliferative colonies occasionally formed on 
the laminin-1-immobilized substrate after 6 d of NPC culture (Fig. 6a). Most cells in these 
colonies expressed GFP driven by the Nanog promoter (Fig. 6b), indicating that these cells 
are in the undifferentiated state. In contrast, these colonies were not found on the LG3-
immobilized substrate (Fig. 6 c and d). This observation suggests that trace of 
undifferentiated miPS cells present in the 4th-generation aggregates were attached to and 
proliferated on the laminin-1-immobilized substrate, but not on the LG3-immobilized 
substrate. We examined this possibility by culturing undifferentiated miPS cells on the 
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LG3- and laminin-1-immobilized substrates. As shown in Fig. 6e, miPS cells adhered on 
the laminin-1-immobilized substrate and expanded approximately 5-fold within 3 d (Fig. 
6g). On the other hand, only a few miPS cells adhered on the LG3-immobilized substrate 





 Many protocols have been reported for the induction of NPCs from ES and iPS cells 
(Chambers et al., 2009; Cai, et al., 2007). However, methods to efficiently expand NPCs 
derived from ES and iPS still remain to be developed for future clinical applications.  In the 
present study, we differentiated miPS cells into NPCs in suspension (Okada. et al., 2008).  
During repeated subcultures, nestin-positive cells reached more than 70% of the total cells 
at the end of the 4th aggregate culture (Fig. 1). However, there are still limitations 
associated with the suspension culture. The most critical problems may be heterogeneity of 
cell populations in an aggregates. The content of the rest of cells are more differentiated 
cells. In addition, cell death occur in a core of a large aggregate due to limited supplies of 
oxygen and nutrients.  
 To date, several research groups have examined various ECMs, such as Matrigel 
(Colleoni et al., 2010), gelatin (Axell et al., 2009), fibronectin (Hong et al., 2008), and 
laminin (Koch et al., 2009) as culture substrates for NPCs. In the present study, nine ECM 
proteins were systematically examined using an array-based method. Except for laminin-5 
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the amounts of ECM proteins immobilized on an array were 0.3-0.5 μg/cm2. Although the 
amount of immobilized laminin-5 was at least 3-fold or so lower than the amounts of the 
other ECMs (Fig. 2), we think that the amount of immobilized laminin-5 was sufficient for 
NPC proliferation. A density of closely packed laminin molecules in a two-dimensional 
lattice on a flat surface was estimated at 1 × 10-12 mol/cm2 (Silva et al., 2004). In addition, 
Massia et al. reported that 1 × 10-14 mol /cm2 of RGD ligands were sufficient for cell 
speeding (Massia et al., 1991). In the present study, the density of immobilized laminin-5 
was approximately 2 × 10-13 mol/cm2. The laminin-5-immobilized surface is expected to 
effectively mediate adhesion and facilitated expansion of NPCs. It was demonstrated in 
Figs. 3 and 4. We did not examine the concentration dependence of other ECMs either on 
NPC adhesion and proliferation. Comparing functions of ECMs at similar surface molar 
concentration may be more relevant, because cell receptors interact with individual 
molecules. However, it is quite difficult to adjust surface molar concentration for different 
ECMs. As mentioned related to laminin-5, we expect sufficient amount of ECMs were 
immobilized on an array for NPC adhesion and proliferation. Using this analytical 
platform, we successfully found that NPCs derived from miPS cells proliferated most 
efficiently on substrates with laminin-1, laminin-5, or Matrigel. In contrast, NPC adhesion 
was poor on substrates with collagen I, collagen IV, or gelatin. These differences may be 
due to dissimilarities in the expression levels of integrins on the cell surface. It has been 
reported that NPCs derived from fetal brain tissue express integrin β1, α3, α6, and α7 and 
integrin complexes such as α3β1, α6β1, and α7β1, all of which constitute specific receptors 
for the laminins (Flanagan et al., 2006; Prowse et al., 2010). On the other hand, the NPCs 
poorly 
 19
expressed collagen-associated integrin α1, α2, α10, and α11 (Prowse et al., 2010). In our 
previous study, neural stem cells derived from rat fetal brain also did not adhere on 
substrate with collagen I, collagen IV, and gelatin (Nakajima et al., 2007).   
 From the clinical point of view, functional substrates used for cell preparation should 
be chemically defined, xeno-free, and low-cost. For these reasons, further investigations 
were conducted using laminin-derived small domains or short peptides that can partially 
replace the function of full-length laminin-1 (Ido et al., 2004; Tashiro et al., 1989). In our 
previous study (Nakaji et al., 2012), LG3 fused with a collagen-binding sequence was 
synthesized, and the engineered protein was incorporated in a collagen hydrogel to design a 
novel carrier for effective cell transplantation. The survival of rat neural stem cells was 
significantly improved in the LG3-incorporated collagen hydrogel due to effective integrin 
ligation, compared to a pure collagen hydrogel (Nakaji et al., 2012). In the present study, 
we used LG3 fused with a His-tag and immobilized this polypeptide on a nickel-chelated 
glass plate to obtain a culture substrate. Although laminin-5 did well in NPC adhesion and 
proliferation at low density, we used LG3 derived from α chain of laminin-1.  It is because 
laminin-1 has been widely studied and we can easily obtain information about three-
dimensional structure and physiological properties of the protein. NPCs adhered well and 
expanded rapidly on the LG3-immobilized substrate (Fig. 5), although the rate of NPC 
proliferation on the LG3-immobilized substrate was slightly slower than that on the 
laminin-1-immobilized substrate. Approximately 98% of cells that expanded on the LG3-
immobilized substrate expressed an NPC marker. 
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 For the clinical use of stem cells, the risk of tumor formation should be minimized as 
much as possible (Fong et al., 2010). Undifferentiated pluripotent stem cells contaminating 
transplants may proliferate and overgrow in the host tissue (Li et al., 2008). In the present 
study, the results of array-based screening indicated that laminin-1 served as a preferable 
substrate for the expansion of NPCs. However, undifferentiated miPS cells cells also 
proliferated to form colonies on the laminin-1-immobilized substrate (Fig. 6). In contrast, 
undifferentiated miPS cells hardly attached and proliferated on the LG3-immobilized 
substrate (Fig. 6 f and g). The observed difference is probably due to distinct specificity of 
LG3 and laminin-1 toward integrins. It is reported that LG3 domain binds most efficiently 
to α6β1 integrin (Belkin et al., 2000), whereas laminin-1 has an affinity for a variety of 
integrin complexes (Durbeej 2010). It is therefore likely that not only NPCs but also 
undifferentiated miPS cells are able to adhere to the substrate with immobilized laminin-1.  
 Accordingly, we demonstrated here that the LG3-immobilized substrate is feasible for 
the selective proliferation of NPCs derived from miPS cells. However, several properties 
differ between human iPS cells and miPS cells (Yu et al., 2008). Therefore, we are 
currently conducting further study to verify the effectiveness of the LG3-immobilized 
substrate for the selective expansion of NPCs derived from human iPS cells. Human NPCs 
highly express integrin α6 and β1 integrin (Prowse et al., 2010). We think the LG3-





 As demonstrated by the array-based assays, laminin-1, laminin-5, and Matrigel are 
effective ECMs for the proliferation and maintenance of NPCs derived from miPS cells. 
When immobilized to a substrate, the LG3 fragment of laminin-1 provides a suitable 
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Figure Captions 
 
Figure 1. Differentiation of miPS cells into NPCs. (a) Experimental protocol of 
differentiation culture. (b) Expression of a pluripotent stem cell maker. miPS cells used in 
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this study expressed GFP driven by the Nanog promoter. Phase-contrast and fluorescent 
micrographs are shown in the upper and lower panels, respectively. (c) Representative 
fluorescence micrographs of primary (left) and 4th-generation (right) aggregates. Cells 
were stained using antibodies against Oct-3/4, GFP, nestin, and -tubulin III. Scale bar: 100 
m. (d) Quantification of Oct-3/4+, Nanog+, nestin+, and -tubulin III+ cells. The data are 
expressed as the mean ± standard deviation for n = 3. *and ** indicates statistical 
significance (Tukey's HSD test, * p < 0.05, ** p < 0.01). Gene expression of 4th aggregates 
was compared with all other aggregates.  
 
  
Figure 2. The surface density of immobilized ECMs. The data are expressed as the 
mean ± standard deviation (n = 3). An asterisk indicates statistical significance (Tukey's 
HSD test, p < 0.05). The laminin-1 immobilized substrate was compared with all other 
substrates.  
 
Figure 3. The number of cells on various substrates with immobilized ECMs determined 1 
day after cell seeding. The data are expressed as the mean ± standard deviation (n = 6). An 
asterisk indicates statistical significance (Tukey's HSD test, p < 0.05).   
 
Figure 4. The effects of various ECMs on NPC proliferation. (a) Phase-contrast (upper) 
and fluorescent (lower) micrographs of NPCs derived from miPS cells cultured for 3 d on 
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the ECM array. The cells were immunologically stained for nestin (red) and -tubulin III 
(green) in the fluorescent images. Identification of immobilized ECMs is shown above the 
micrographs. Scale bar: 100 m. (b) The number of cells on surfaces with immobilized 
ECMs determined 3 d after seeding. The data are expressed as the mean ± standard 
deviation for n = 3. Closed and open boxes indicate the fractions of nestin– and nestin+ 
cells, respectively. An asterisk indicates statistical significance (Tukey's HSD test, p < 
0.05).   
 
Figure 5.  Proliferation of NPCs on the LG3-immobilized substrate. (a) Phase-contrast 
micrograph of cells cultured for 3 d. (b) Fluorescence micrograph of cells stained for nestin 
(red), -tubulin III (green), and cell nuclei (blue).  Scale bar: 100 m. (c) The number of 
cells on the LG3- and laminin-1-immobilized substrates. The data are expressed as the 
mean ± standard deviation for n = 3. Closed and hatched boxes indicate the number of 
cells after 1 d and 3 d of culture, respectively. *and ** indicates statistical significance 
(Tukey's HSD test, * p < 0.05, ** p < 0.01). 
 
Figure 6. The proliferation of undifferentiated miPS cells on the laminin-1-immobilized 
substrate. Phase-contrast micrographs of miPS cell-derived NPCs cultured for 6 d on the 
substrate with immobilized laminin-1 (a, c) or LG3 (b, d). A circle indicates a highly 
proliferative colony formed on the laminin-1-immobilized substrate. Scale bar: 200 m. (c, 
d) Fluorescence micrographs of cells stained for GFP (green) and cell nuclei (blue). Scale 
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bar: 100 m. (e, f) Phase-contrast micrographs of undifferentiated miPS cells (miPSC) 
cultured for 3 d on the substrate with immobilized laminin-1 (e) or LG3 (f). (g) The number 
of cells on the substrate with immobilized LG3 and laminin-1. The data are expressed as 
the mean ± standard deviation for n = 3. Closed and hatched boxes indicate the number of 
cells after 1 d and 3 d of culture, respectively. Cells were seeded onto the substrate with 
immobilized LG3 and laminin-1 at a density of 2.0  104 cells/cm2. An asterisk indicates 
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